Ardelyx appoints Mark Kaufmann as chief business officer

Role includes business development, licensing and strategic planning

Ardelyx, a US developer of oral therapeutics to correct metabolic disorders, has appointed Mark Kaufmann to the newly created position of chief business officer. The role at the Fremont, CA company will include business and corporate development, licensing, and strategic planning.

Kaufmann was formerly chief executive of Allostera and Celmed BioSciences.

‘Mark’s deep understanding of the biotechnology business, coupled with his substantial experience at the most senior levels in business development and planning will serve Ardelyx well during our next phase of corporate development,’ said Mike Raab, chairman and ceo of Ardelyx.

Kaufmann has more than 20 years of experience in the biopharmaceutical industry in the US and Canada in business and corporate development roles.

Most recently, he was president and ceo of Allostera Pharma, a venture-backed, preclinical company focused on autoimmune diseases.

Prior to joining Allostera, Kaufmann was president and ceo of Celmed BioSciences, where he was responsible for raising funds and selling the company to Kiadis Pharma, a European biotechnology company. He has also held roles at Nexia Biotechnologies, Conceptis Technologies and MedImmune.

You may also like

Ingredients

Therapeutic: tenapanor for hyperphosphataemia

Patients with chronic kidney disease being treated with dialysis are at risk of developing hyperphosphataemia. This elevation of phosphorus levels is associated with cardiovascular morbidity and mortality
Manufacturing

Sapio Sciences and Ultima Genomics to work together in advancing multiomics research

The partnership delivers global, end-to-end solutions aimed at making genomics research more streamlined and accessible
Cell & Gene Therapy

Cytiva and WhiteLab Genomics team up to use AI to accelerate cell line development

Collaboration will accelerate stable cell line development in AAV genomic medicine development and ultimately also shorten the development timeline to clinic
Manufacturing

Watson-Marlow to showcase new Bredel CIP pump and innovative fluid handling solutions at PPMA

Watson-Marlow Fluid Technology Solutions (WMFTS) will unveil the new Bredel CIP pump as well as highlight its advanced fluid management technologies during PPMA at the NEC in Birmingham, UK, from 23-25 September 2025
Manufacturing

Evonik and Ethris partner to develop novel lipid nanoparticle platform for nucleic acid delivery

The partnership will enable Evonik to bring more stable and targeted nucleic acid therapies and vaccines to market
Manufacturing

Continuous innovation: redefining the future of pharmaceutical manufacturing

In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
Manufacturing

LGC Group opens $100m Organic Chemistry Synthesis Centre of Excellence in Ontario

The new facility in Vaughn is one of the largest of its kind in the world and will ship to more than 170 countries
Subscribe now